Izzy's questions to Integra Lifesciences Holdings Corp (IART) leadership • Q2 2025
Question
Izzy, on for Ryan Zimmerman at BTIG, requested more color on the headwinds in the ENT business that led to below-expectation growth and asked for the sustainable long-term growth outlook. She also asked if recent FDA recalls were contemplated in guidance.
Answer
President and CEO Mojdeh Poul attributed the soft Q2 ENT growth to a tough prior-year comparison in capital sales and increased payer pressure on balloon sinuplasty, but noted strong double-digit growth in other areas like Eustachian tube balloon dilation. She stated the outlook for mid-single-digit growth in the second half remains, with no change to the long-term view. EVP & CFO Lea Daniels Knight confirmed that the recent recalls for MicroFrance and perforators were known and already factored into the guidance provided in May.